BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haidar G, Boeckh M, Singh N. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. J Infect Dis 2020;221:S23-31. [PMID: 32134486 DOI: 10.1093/infdis/jiz454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Karaba AH, Figueroa A, Werbel WA, Dioverti MV, Steinke SM, Ray SC, Cox AL, Avery RK. Interleukin-18 and tumor necrosis factor-α are elevated in solid organ transplant recipients with possible cytomegalovirus end-organ disease. Transpl Infect Dis 2021;:e13682. [PMID: 34216086 DOI: 10.1111/tid.13682] [Reference Citation Analysis]
2 Lazar K, Kussmann T, Pawelec G, Pöschel S, Goelz R, Hamprecht K, Wistuba-Hamprecht K. Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation. Front Immunol 2021;12:723010. [PMID: 34566980 DOI: 10.3389/fimmu.2021.723010] [Reference Citation Analysis]
3 Di Cristanziano V, Affeldt P, Trappe M, Wirtz M, Heger E, Knops E, Kaiser R, Stippel D, Müller RU, Holtick U, Scheid C, Kann M, Kurschat CE, Grundmann F. Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients. Microorganisms 2021;9:1666. [PMID: 34442744 DOI: 10.3390/microorganisms9081666] [Reference Citation Analysis]
4 García-Ríos E, Nuévalos M, Mancebo FJ, Pérez-Romero P. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients? Front Immunol 2021;12:657144. [PMID: 33968058 DOI: 10.3389/fimmu.2021.657144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Limaye AP. Unexpected CMV replication kinetics in CMV- donor seropositive recipient seronegative liver transplant recipients receiving preemptive antiviral therapy. J Infect Dis 2021:jiab132. [PMID: 33755176 DOI: 10.1093/infdis/jiab132] [Reference Citation Analysis]
6 Houldcroft CJ, Jackson SE, Lim EY, Sedikides GX, Davies EL, Atkinson C, McIntosh M, Remmerswaal EBM, Okecha G, Bemelman FJ, Stanton RJ, Reeves M, Wills MR. Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay. Front Cell Infect Microbiol 2020;10:275. [PMID: 32670891 DOI: 10.3389/fcimb.2020.00275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ligat G, Alain S, Hantz S. Towards a Prophylactic Vaccine for the Prevention of HCMV Infection. Vaccines (Basel) 2021;9:968. [PMID: 34579205 DOI: 10.3390/vaccines9090968] [Reference Citation Analysis]
8 Teschner D, Knop J, Piehl C, Junker S, Witzke O. Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection 2022. [PMID: 35633464 DOI: 10.1007/s15010-022-01847-2] [Reference Citation Analysis]
9 Abbas A, Zimmer AJ, Florescu D. Viral Enteritis in Solid-Organ Transplantation. Viruses 2021;13:2019. [PMID: 34696449 DOI: 10.3390/v13102019] [Reference Citation Analysis]
10 Joharji H, Alaidaros F, Koujan H, Hamad A, Almaghrabi RS, Zidan A, Broering D, Al-Jedai A. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient. Transplant Proc 2022:S0041-1345(22)00399-2. [PMID: 35842318 DOI: 10.1016/j.transproceed.2022.04.021] [Reference Citation Analysis]
11 Yun TJ, Igarashi S, Zhao H, Perez OA, Pereira MR, Zorn E, Shen Y, Goodrum F, Rahman A, Sims PA, Farber DL, Reizis B. Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells. Sci Immunol 2021;6:eabc7302. [PMID: 33811059 DOI: 10.1126/sciimmunol.abc7302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Imlay HN, Kaul DR. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clin Infect Dis 2021;73:156-60. [PMID: 33197929 DOI: 10.1093/cid/ciaa1713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rinaldo CR. Cytomegalovirus: 40 years and still the major viral cofactor in HIV infection. AIDS 2022;36:1311-3. [PMID: 35833683 DOI: 10.1097/QAD.0000000000003284] [Reference Citation Analysis]
14 Pan L, Wu F, Cai Q, Xu Z, Hu H, Tang T, Yue R, Hou Y, Zhang X, Fang Y, Huang X, Kang Y. Whole Genome Profiling of Lung Microbiome in Solid Organ Transplant Recipients Reveals Virus Involved Microecology May Worsen Prognosis. Front Cell Infect Microbiol 2022;12:863399. [DOI: 10.3389/fcimb.2022.863399] [Reference Citation Analysis]
15 Groves IJ, Jackson SE, Poole EL, Nachshon A, Rozman B, Schwartz M, Prinjha RK, Tough DF, Sinclair JH, Wills MR. Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. Proc Natl Acad Sci U S A 2021;118:e2023025118. [PMID: 33619107 DOI: 10.1073/pnas.2023025118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
16 Halpern-Cohen V, Blumberg EA. New Perspectives on Antimicrobial Agents: Maribavir. Antimicrob Agents Chemother 2022;:e0240521. [PMID: 35916518 DOI: 10.1128/aac.02405-21] [Reference Citation Analysis]
17 Ugwu N, Galan A, Nelson CA. Multiple, Tender Perianal Ulcers in a Young Woman. JAMA Dermatol 2021;157:458-9. [PMID: 33595629 DOI: 10.1001/jamadermatol.2020.5764] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Otto WR, Green A. Antiviral Therapeutics in Pediatric Transplant Recipients. Infectious Disease Clinics of North America 2022;36:125-46. [DOI: 10.1016/j.idc.2021.11.004] [Reference Citation Analysis]
19 Mo W, Chen X, Zhang X, Wang S, Li L, Zhang Y. The Potential Association of Delayed T Lymphocyte Reconstitution Within Six Months Post-Transplantation With the Risk of Cytomegalovirus Retinitis in Severe Aplastic Anemia Recipients. Front Cell Infect Microbiol 2022;12:900154. [DOI: 10.3389/fcimb.2022.900154] [Reference Citation Analysis]
20 Huang X, Sun P, Qin Y, Wang XJ, Wang M, Lin Y, Zhou R, Hu W, Liu Q, Yu X, Qin A. Disulfiram attenuates MCMV-Induced pneumonia by inhibition of NF-κB/NLRP3 signaling pathway in immunocompromised mice. Int Immunopharmacol 2021;103:108453. [PMID: 34959186 DOI: 10.1016/j.intimp.2021.108453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cheng WY, Avery RK, Thompson-Leduc P, Cheung HC, Bo T, Duh MS, Hirji I. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation. J Med Econ 2022;:1-39. [PMID: 35240904 DOI: 10.1080/13696998.2022.2046388] [Reference Citation Analysis]
22 Shi Y, Lerner AH, Rogers R, Vieira K, Merhi B, Mecadon K, Osband AJ, Bayliss G, Gohh R, Morrissey P, Farmakiotis D. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients. Prog Transplant 2021;31:368-76. [PMID: 34839729 DOI: 10.1177/15269248211046037] [Reference Citation Analysis]
23 Khawaja F, Spallone A, Kotton CN, Chemaly RF. Cytomegalovirus infection in transplant recipients: Newly approved additions to our armamentarium. Clin Microbiol Infect 2022:S1198-743X(22)00348-2. [PMID: 35843567 DOI: 10.1016/j.cmi.2022.07.001] [Reference Citation Analysis]
24 Scheuenpflug J, Kropeit D, Erb-Zohar K, Theis JGW, Stobernack HP, McCormick D, Zimmermann H, Rübsamen-Schaeff H. The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 34812580 DOI: 10.1002/cpdd.1043] [Reference Citation Analysis]
25 Mella A, Mariano F, Dolla C, Gallo E, Manzione AM, Di Vico MC, Cavallo R, De Rosa FG, Costa C, Biancone L. Bacterial and Viral Infection and Sepsis in Kidney Transplanted Patients. Biomedicines 2022;10:701. [DOI: 10.3390/biomedicines10030701] [Reference Citation Analysis]
26 Furihata K, Hamada I, Niwa T, Watanabe T, Ezoe S. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev 2022. [PMID: 34989174 DOI: 10.1002/cpdd.1065] [Reference Citation Analysis]
27 Haidar G, Garner W, Hill JA. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. Curr Opin Infect Dis 2020;33:449-57. [PMID: 33009139 DOI: 10.1097/QCO.0000000000000679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
28 Kropeit D, McCormick D, Erb-Zohar K, Stobernack HP, Zimmermann H, Rübsamen-Schaeff H. Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects. Clin Pharmacol Drug Dev 2021. [PMID: 34714967 DOI: 10.1002/cpdd.1027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]